The overall objective of the project is the search for diagnostic and prognostic biomarkers for amyotrophic Lateral Sclerosis (ALS) easily applicable in clinical practice. Initially, the identification study of plasma microRNAs of patients with ALS (observed as biomarkers in animal models) will be carried out at the time of diagnosis and a second study to see the modification of this expression with the evolution of the disease, which will be an innovative approach to the study of this disease. On the other hand, and based on the results obtained regarding the modification of blood stem cells in model animals, we intend to carry out a proteomics study that allows us to know if the modification in blood proteins related to these cell types can be appropriate markers and diagnostics of the disease in the animal model (transgenic mice SOD1G93A). This fact seems to us to be very interesting, since the performance of an ELISA test (whether or not accompanied by other biomarkers) could foresee early the development of the disease in patients with both ALS and Temporary Front Dementia. On the other hand and not least, the results obtained could in the future target new therapies for the disease. In short, the collaboration that will be maintained with the Hospital 12 October Madrid for the achievement of this project, will favor a great advance in the knowledge of the disease, which will be reflected in the results obtained.